10 recruiting, 3 active not recruiting, 1 available, 1 completed. 6 Phase 2, 6 Phase 3, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 6 | Recruiting 4, Active not recruiting 2 |
| Phase 1 | 5 | Recruiting 3, Completed 1, Not yet recruiting 1 |
Follow Odronextamab: new trials by email Literature Review of Odronextamab trials Research Report on Odronextamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 36 | 2026-12-07 | 2026-10-21 |
| Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis Vonsetamig, Odronextamab - Lupus Nephritis (LN) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 90 | 2025-12-22 | 2026-09-14 |
| Odronextamab in Low Tumor Volume Advanced FL Odronextamab - Follicular Lymphoma, Lymphoma | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | 35 | 2025-09-08 | 2026-03-13 |
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 23 | 2025-08-14 | 2026-09-16 |
| Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy Chimeric Antigen Receptor T-Cell Therapy, Odronextamab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | University of California, Davis | 34 | 2025-08-07 | 2026-07-08 |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | University of Birmingham | 210 | 2024-05-02 | 2026-02-20 |
| A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Odronextamab, Ifosfamide, Carboplatin - B-Cell Non-Hodgkin Lymphoma (B-NHL) | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 216 | 2024-02-15 | 2026-05-11 |
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma Odronextamab, Lenalidomide, Rituximab - Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 580 | 2023-12-28 | 2026-10-07 |
| A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma Odronextamab, Rituximab, Cyclophosphamide - Diffuse Large B-cell Lymphoma (DLBCL) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 904 | 2023-12-13 | 2026-10-07 |
| A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 822 | 2023-12-12 | 2026-10-06 |
| A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 733 | 2023-11-14 | 2026-02-06 |
| A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas Odronextamab, REGN5837 - B-cell Non-Hodgkins Lymphoma (B-NHL) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 107 | 2023-04-20 | 2026-05-19 |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies Odronextamab - B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 515 | 2019-11-13 | 2026-07-31 |
| A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies cemiplimab, odronextamab - Relapsed/Refractory Aggressive B-Cell Lymphoma | Phase 1 | Completed | Regeneron Pharmaceuticals | 105 | 2016-01-11 | 2026-06-02 |
| A Compassionate Use (CU) Program of Odronextamab Odronextamab - Relapsed or Refractory (R/R) Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL) | Available | Regeneron Pharmaceuticals | 2026-10-09 |
Lymphoma, Follicular (6) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, B-Cell (5) · Recurrence (5) · Lymphoma, B-Cell, Marginal Zone (2) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Lymphoma (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1)
Regeneron Pharmaceuticals (11) · City of Hope Medical Center (1) · Gottfried von Keudell, MD PhD (1) · University of Birmingham (1) · University of California, Davis (1) · University of Washington (1)
United States (12) · Spain (9) · Australia (7) · France (7) · Germany (7) · Taiwan (7) · United Kingdom (7) · Austria (6) · Poland (6) · South Korea (6) · Belgium (5) · Brazil (5) · Israel (5) · Italy (5) · Turkey (Türkiye) (5)
Alexey V Danilov (1) · Amos Burke (1) · Gottfried Von Keudell, MD, PhD (1) · Joseph M Tuscano, MD (1) · Mengyang Di, MD, PhD (1)
PMID 40097657, PMID 40472301, PMID 40902079, PMID 41766170
2015 (1), 2017 (1), 2023 (1), 2025 (1), P30CA033572 (1), P30CA093373 (1)